Chemical modifications of nucleic acid drugs and their delivery systems for gene-based therapy

Med Res Rev. 2018 May;38(3):829-869. doi: 10.1002/med.21479. Epub 2018 Jan 5.

Abstract

Gene-based therapy is one of essential therapeutic strategies for precision medicine through targeting specific genes in specific cells of target tissues. However, there still exist many problems that need to be solved, such as safety, stability, selectivity, delivery, as well as immunity. Currently, the key challenges of gene-based therapy for clinical potential applications are the safe and effective nucleic acid drugs as well as their safe and efficient gene delivery systems. In this review, we first focus on current nucleic acid drugs and their formulation in clinical trials and on the market, including antisense oligonucleotide, siRNA, aptamer, and plasmid nucleic acid drugs. Subsequently, we summarize different chemical modifications of nucleic acid drugs as well as their delivery systems for gene-based therapeutics in vivo based on nucleic acid chemistry and nanotechnology methods.

Keywords: antisense oligonucleotides; chemical modifications; gene delivery; gene-based therapeutics; nucleic acid drugs; precision medicine; siRNA.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Clinical Trials as Topic
  • Drug Delivery Systems*
  • Genetic Therapy*
  • Humans
  • Nanoparticles / chemistry
  • Nucleic Acids / chemistry*
  • Pharmaceutical Preparations / chemistry*

Substances

  • Nucleic Acids
  • Pharmaceutical Preparations